Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
| ▸ | GIPR | P48546 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100829 | 0.92 | PTPN1 (0.44) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL2472074 | 0.91 | TP53 (0.53) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL2471479 | 0.89 | MAPT (0.49) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL2468727 | 0.88 | TP53 (0.50) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL5100796 | 0.87 | MAPK14 (0.55) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL2470655 | 0.87 | MAPT (0.49) | TP53MAPTLMNAPOLBKDM4E | |
| SCHEMBL14208479 | 0.86 | PTPN1 (0.53) | TP53MAPTLMNAPTPN1POLB | |
| SCHEMBL2469743 | 0.85 | MAPT (0.46) | TP53MAPTPTPN1POLBSMN1; SMN2 | |
| SCHEMBL2469736 | 0.85 | MAPT (0.46) | TP53MAPTPTPN1POLBSMN1; SMN2 | |
| SCHEMBL2473831 | 0.85 | MAPT (0.45) | TP53MAPTPTPN1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | claimed |
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189583-A1 | Aryl dicarboxamides | GPR119, PTPRS, ECHS1 | TP53 1795/4885MAPT 4883/4885LMNA 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.